Trial Profile

A phase II study evaluating bexmarilimab with PD-1 blockade

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bexmarilimab (Primary)
Indications Bladder cancer; Head and neck cancer; Non-small cell lung cancer
Focus Proof of concept; Therapeutic Use
Acronyms BEXCOMBO
Sponsors Faron Pharmaceuticals

Most Recent Events

01 Sep 2023 New trial record
29 Aug 2023 According to a Faron Pharmaceuticals media release, Phase II BEXCOMBO protocol has been approved by the FDA. Preparations are ongoing for initiation of this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com